World's Best Scientists 2026 revealed!
Takayuki Yoshino

Takayuki Yoshino

D-Index & Metrics

Medicine

D-Index
87
Citations
52706
World Ranking
13383
National Ranking
396

Overview

Takayuki Yoshino is affiliated with the University of Tsukuba in Japan and specializes in medicine with a focus on oncology. Their research portfolio includes extensive work in subfields such as oncology, pulmonary and respiratory medicine, cancer research, pathology and forensic medicine, and surgery.

Their work covers a variety of main topics related to cancer, including colorectal cancer treatments and studies, genetic factors in colorectal cancer, cancer genomics and diagnostics, gastric cancer management and outcomes, lung cancer treatments and mutations, colorectal cancer surgical treatments, and cancer treatment and pharmacology.

Yoshino has frequently published in leading oncology and medical journals. The primary venues for their research include:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • ESMO Open
  • International Journal of Clinical Oncology
  • JCO Precision Oncology

Frequent coauthors of Yoshino include:

  • Yoshiaki Nakamura
  • Hideaki Bando
  • Eiji Oki
  • Takeshi Kato
  • Hiroya Taniguchi

Among recent significant publications by Yoshino are:

  • Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer, 2020, New England Journal of Medicine
  • Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up, 2022, Annals of Oncology
  • Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, 2020, Annals of Oncology
  • Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study, 2022, The Lancet Oncology
  • ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group, 2022, Annals of Oncology

Best Publications

  • ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

    E. Van Cutsem;A. Cervantes;R. Adam;A. Sobrero

  • Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

    Axel Grothey;Eric Van Cutsem;Alberto Sobrero;Salvatore Siena

  • Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer

    Toshiaki Watanabe;Michio Itabashi;Yasuhiro Shimada;Shinji Tanaka

  • Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.

    Thierry André;Kai-Keen Shiu;Tae Won Kim;Benny Vittrup Jensen

  • Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer

    Robert J Mayer;Eric Van Cutsem;Alfredo Falcone;Takayuki Yoshino

  • Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer

    Scott Kopetz;Axel Grothey;Rona Yaeger;Eric Van Cutsem

  • Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): A randomised, double-blind, multicentre, phase 3 study

    Josep Tabernero;Takayuki Yoshino;Allen Lee Cohn;Radka Obermannova

  • Duration of Adjuvant Chemotherapy for Stage III Colon Cancer

    Axel Grothey;Alberto F. Sobrero;Anthony F. Shields;Takayuki Yoshino

  • Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164

    Dung T Le;Tae Won Kim;Eric Van Cutsem;Ravit Geva

  • Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer

    Toshiaki Watanabe;Michio Itabashi;Yasuhiro Shimada;Shinji Tanaka

  • Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS.

    T. Yoshino;D. Arnold;H. Taniguchi;G. Pentheroudakis

  • Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer

    Ryan B. Corcoran;Thierry Andre;Chloe E. Atreya;Jan H.M. Schellens

  • The World Health Organization classification of malignant lymphomas in Japan: Incidence of recently recognized entities

    M. Fujita;K. Yamashiro;R. Ichinohasama;N. Nakamura

  • TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial

    Takayuki Yoshino;Nobuyuki Mizunuma;Kentaro Yamazaki;Tomohiro Nishina

  • Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial

    Josep Tabernero;Heinz Josef Lenz;Salvatore Siena;Alberto Sobrero

  • Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study.

    Josep Tabernero;Axel Grothey;Eric van Cutsem;Rona Yaeger

  • Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies.

    Yoshiaki Nakamura;Hiroya Taniguchi;Masafumi Ikeda;Hideaki Bando

  • Chromoendoscopy using indigo carmine dye spraying with magnifying observation is the most reliable method for differential diagnosis between non-neoplastic and neoplastic colorectal lesions: a prospective study.

    K.-I. Fu;Y. Sano;S. Kato;T. Fujii

  • Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial.

    Salvatore Siena;Maria Di Bartolomeo;Kanwal Raghav;Toshiki Masuishi

  • Iatrogenic perforation associated with therapeutic colonoscopy: a multicenter study in Japan.

    Keisei Taku;Yasushi Sano;Kuang-I Fu;Yutaka Saito

Frequent Co-Authors

Atsushi Ohtsu
Atsushi Ohtsu Juntendo University
Toshihiko Doi
Toshihiko Doi Okayama University
Kohei Shitara
Kohei Shitara Yahoo (United Kingdom)
Axel Grothey
Axel Grothey University of Tennessee at Knoxville
Josep Tabernero
Josep Tabernero Vall d´Hebron Institute of Oncology
Kei Muro
Kei Muro National Cancer Research Institute, UK
Thierry André
Thierry André Université Paris Cité
Atsushi Ochiai
Atsushi Ochiai University of Tokyo
Alfredo Falcone
Alfredo Falcone University of Pisa

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

The path to a medical career in the USA offers various online degree options and alternative career routes. Besides the traditional MD or DO programs, students can explore in-demand health professions by enrolling in online degrees such as a health care administration degree online. This fully digital route is ideal for those interested in the business and management side of healthcare.

For professionals seeking to advance, a graduate degree like the cheapest online mha (Master of Healthcare Administration) is a cost-effective way to build leadership skills and qualify for senior roles. Nurses looking to reach the top of clinical practice can consider enrolling in the best dnp programs online to earn a Doctor of Nursing Practice without stepping away from work.

Pharmacists who want to earn a doctorate can benefit from pharmd online programs that provide flexible learning for diverse career opportunities. These online pathways are not only more accessible but often more affordable, supporting a wide range of healthcare ambitions.

Best Scientists Citing Takayuki Yoshino

Trending Scientists

Recently Published Articles